Medicina clinica · 2010
[Use and clinical implications of anticoagulation maintenance after a successful cardioversion].
Аннотация на английскомСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alegret Josep M, Viñolas Xavier, Villacastín Julián, Martínez Juan G, Pachón Nicolás, Crespo Francisco, en nombre de los investigadores del registro REVERSE
Аннотация
PATIENTS AND METHOD: We studied the use of anticoagulation following cardioversion due to persistent atrial fibrillation in 422 patients with low or moderate risk of embolism, as well as its benefit during a follow-up of one year.
RESULTS: Oral anticoagulation was maintained after the first month in 80% of patients who showed sinus rhythm and in 43% after 12 months. Its maintenance in patients in sinus rhythm was related to a trend to lower incidence of embolic events (2.8% vs. 0.7%; p=0.37). The incidence of major bleeding in patients who remained on oral anticoagulation was 4.9%, and age ≥75 years (OR 5.3; p=0.02) was the only independently related factor.
CONCLUSIONS: Anticoagulation is frequently maintained to long-term in patients without high risk of embolism but it seems that this treatment doe not have a favorable risk profile with a CHADS(2)=0 or 1 older than ≥75.
RESULTS: Oral anticoagulation was maintained after the first month in 80% of patients who showed sinus rhythm and in 43% after 12 months. Its maintenance in patients in sinus rhythm was related to a trend to lower incidence of embolic events (2.8% vs. 0.7%; p=0.37). The incidence of major bleeding in patients who remained on oral anticoagulation was 4.9%, and age ≥75 years (OR 5.3; p=0.02) was the only independently related factor.
CONCLUSIONS: Anticoagulation is frequently maintained to long-term in patients without high risk of embolism but it seems that this treatment doe not have a favorable risk profile with a CHADS(2)=0 or 1 older than ≥75.